サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1753423

セリアック病治療薬の世界市場

Celiac Diseases Drugs

出版日
ページ情報
英文 367 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.58円
セリアック病治療薬の世界市場
出版日: 2025年06月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 367 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

セリアック病治療薬の世界市場は2030年までに26億米ドルに達する見込み

2024年に7億7,620万米ドルと推定されるセリアック病治療薬の世界市場は、分析期間2024-2030年にCAGR 22.2%で成長し、2030年には26億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるファーストライン治療は、CAGR 24.4%を記録し、分析期間終了時には19億米ドルに達すると予測されます。セカンドライン治療セグメントの成長率は、分析期間中CAGR 17.6%と推定されます。

米国市場は2億1,150万米ドルと推定、中国はCAGR 30.0％で成長すると予測

米国のセリアック病治療薬市場は、2024年に2億1,150万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR 30.0％を牽引し、2030年には予測市場規模6億2,900万米ドルに達すると予測されます。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ17.5％と20.0％と予測されています。欧州では、ドイツがCAGR約18.7%で成長すると予測されています。

世界のセリアック病治療薬市場- 主要動向と促進要因のまとめ

セリアック病治療薬市場の需要が急増しているのはなぜか？

世界のセリアック病治療薬市場は、診断された症例の有病率の増加と疾患に対する意識の高まりに牽引され、著しい成長を遂げています。セリアック病は、グルテンの摂取によって引き起こされる自己免疫疾患であり、米国では約100人に1人が罹患しています。この過小診断が、従来のグルテンフリー食以外の効果的な治療の必要性を強調しています。厳格なグルテン除去食の限界は、その順守の課題や不注意によるグルテン暴露のリスクなどであり、医薬品による介入を求める声が高まっています。患者はグルテンによって引き起こされる免疫反応を緩和する代替療法を求めており、グルテンの病態生理学の様々な側面をターゲットにした新薬の開発につながっています。グルテンペプチドを分解する薬剤、免疫系を調節する薬剤、腸の粘膜を保護する薬剤などです。このような薬剤のパイプラインが充実してきていることは、セリアック病のより包括的な管理戦略へのシフトを示しています。

技術の進歩は治療の選択肢にどのような影響を与えているか？

医薬品開発における技術革新は、セリアック病の治療選択肢を広げる上で極めて重要な役割を果たしています。バイオテクノロジーの進歩により、免疫反応を引き起こす前にグルテンペプチドを分解する酵素療法が開発されています。さらに、グルテンに対する耐性を誘導し、患者に長期的な解決策を提供する可能性のある免疫調節治療の研究も進められています。こうした最先端の治療法は現在臨床試験中で、腸の炎症を抑え、患者の予後を改善する有望な結果を示しているものもあります。

さらに、個別化医療の統合により、個々の患者のプロファイルに合わせた治療法の開発が可能になりつつあります。遺伝子、免疫、マイクロバイオームのデータを分析することで、研究者は介入すべき特定のターゲットを特定し、新しい治療法の有効性を高めることができます。このプレシジョン・メディシンのパラダイムは、セリアック病の管理に革命をもたらし、より効果的で個別化された治療の選択肢を提供すると期待されています。

規制と市場力学は業界の形成にどのような役割を果たしているか？

規制の枠組みと市場力学は、セリアック病治療薬市場の軌跡に大きな影響を与えています。規制当局が特定のセリアック病治療薬に希少疾病用医薬品（オーファンドラッグ）の指定を与えることで、市場独占権や税控除などのインセンティブが得られ、製薬企業がこの分野に投資することを奨励しています。これらのインセンティブは、医薬品開発や臨床試験に伴う高額なコストを相殺する上で極めて重要です。

研究開発資金の増加など市場力学も業界の成長に寄与しています。公的・民間投資は、新規治療標的の発見と臨床試験の進展に拍車をかけています。さらに、バイオテクノロジー企業と学術機関との連携がイノベーションを促進し、研究成果の実行可能な治療法への転換を加速させています。これらの要因が総合的に、セリアック病治療薬市場の拡大に資する環境を作り出しています。

市場成長を促進する主な要因は何か？

セリアック病治療薬市場の成長は、いくつかの要因によってもたらされます。最も大きな要因は、セリアック病と診断される患者の増加であり、これにより効果的な治療に対する需要が高まっています。特に酵素療法や免疫調整剤などの医薬品開発における技術的進歩は、患者が利用できる治療薬の選択肢を広げています。グルテンフリーの食事療法には、アドヒアランスの課題や交差汚染のリスクなどの限界があり、医薬品による介入の必要性が強調されています。希少疾病用医薬品（オーファンドラッグ）に指定されるなどの規制上の優遇措置が、セリアック病の研究開発への投資を促しています。さらに、認知度の向上とアドボカシー活動により、診断の早期化と患者関与の増加が進み、市場の拡大に拍車をかけています。これらの要因が相まって、セリアック病治療薬市場は今後数年間で持続的な成長を遂げると思われます。

セグメント

治療タイプ（ファーストライン治療、セカンドライン治療）、投与ルート（経口ルート、非経口ルート）、流通チャネル（病院・専門クリニック、専門薬局、小売薬局、オンラインプラットフォーム）

調査対象企業の例（注目の37社）

  • ActoBio Therapeutics
  • Allero Therapeutics B.V.
  • Amgen Inc.
  • Anokion SA
  • BioLineRx Ltd.
  • Calypso Biotech
  • Dr. Falk Pharma GmbH
  • Entero Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd
  • Immunic Therapeutics
  • ImmusanT Inc.
  • Innovate Biopharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Nemysis Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zedira GmbH

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36491

Global Celiac Diseases Drugs Market to Reach US$2.6 Billion by 2030

The global market for Celiac Diseases Drugs estimated at US$776.2 Million in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 22.2% over the analysis period 2024-2030. First Line Treatment, one of the segments analyzed in the report, is expected to record a 24.4% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Second-Line Treatment segment is estimated at 17.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$211.5 Million While China is Forecast to Grow at 30.0% CAGR

The Celiac Diseases Drugs market in the U.S. is estimated at US$211.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$629.0 Million by the year 2030 trailing a CAGR of 30.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.5% and 20.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 18.7% CAGR.

Global Celiac Diseases Drugs Market - Key Trends & Drivers Summarized

Why Is the Celiac Disease Drug Market Experiencing a Surge in Demand?

The global celiac disease drug market is witnessing significant growth, driven by an increasing prevalence of diagnosed cases and a heightened awareness of the disease. Celiac disease, an autoimmune disorder triggered by gluten ingestion, affects approximately 1 in 100 individuals in the United States, with many cases remaining undiagnosed . This underdiagnosis underscores the need for effective treatments beyond the traditional gluten-free diet. The limitations of a strict gluten-free diet, including challenges in adherence and the risk of inadvertent gluten exposure, have propelled the demand for pharmaceutical interventions. Patients are seeking alternative therapies that can mitigate the immune response triggered by gluten, leading to the development of novel drugs targeting various aspects of the disease's pathophysiology. These include agents that degrade gluten peptides, modulate the immune system, or protect the intestinal lining. The growing pipeline of such drugs indicates a shift towards more comprehensive management strategies for celiac disease.

How Are Technological Advancements Influencing Treatment Options?

Technological innovations in drug development are playing a pivotal role in expanding treatment options for celiac disease. Advancements in biotechnology have facilitated the creation of enzyme therapies designed to break down gluten peptides before they can trigger an immune response. Additionally, research into immunomodulatory treatments aims to induce tolerance to gluten, potentially offering a long-term solution for patients. These cutting-edge therapies are currently undergoing clinical trials, with some showing promising results in reducing intestinal inflammation and improving patient outcomes.

Moreover, the integration of personalized medicine approaches is enabling the development of treatments tailored to individual patient profiles. By analyzing genetic, immunological, and microbiome data, researchers can identify specific targets for intervention, enhancing the efficacy of new therapies. This precision medicine paradigm is expected to revolutionize the management of celiac disease, offering more effective and individualized treatment options.

What Role Do Regulatory and Market Dynamics Play in Shaping the Industry?

Regulatory frameworks and market dynamics are significantly influencing the trajectory of the celiac disease drug market. The designation of orphan drug status for certain celiac disease treatments by regulatory bodies provides incentives such as market exclusivity and tax credits, encouraging pharmaceutical companies to invest in this area. These incentives are crucial in offsetting the high costs associated with drug development and clinical trials.

Market dynamics, including increased funding for research and development, are also contributing to the growth of the industry. Public and private investments are fueling the discovery of novel therapeutic targets and the advancement of clinical trials. Additionally, collaborations between biotech firms and academic institutions are fostering innovation and accelerating the translation of research findings into viable treatments. These factors collectively create a conducive environment for the expansion of the celiac disease drug market.

What Are the Key Drivers Propelling Market Growth?

The growth in the celiac disease drug market is driven by several factors. Foremost is the increasing prevalence of diagnosed celiac disease cases, which heightens the demand for effective treatments. Technological advancements in drug development, particularly in enzyme therapies and immunomodulators, are expanding the therapeutic arsenal available to patients. The limitations of the gluten-free diet, including challenges in adherence and the risk of cross-contamination, underscore the need for pharmaceutical interventions. Regulatory incentives, such as orphan drug designations, are encouraging investment in celiac disease research and development. Furthermore, heightened awareness and advocacy efforts are leading to earlier diagnosis and increased patient engagement, further fueling market expansion. Collectively, these factors are propelling the celiac disease drug market towards sustained growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Celiac Diseases Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy Type (First Line Treatment, Second-Line Treatment); Administration Route (Oral Route, Parenteral Route); Distribution Channel (Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies, Online Platforms)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

  • ActoBio Therapeutics
  • Allero Therapeutics B.V.
  • Amgen Inc.
  • Anokion SA
  • BioLineRx Ltd.
  • Calypso Biotech
  • Dr. Falk Pharma GmbH
  • Entero Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd
  • Immunic Therapeutics
  • ImmusanT Inc.
  • Innovate Biopharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Nemysis Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zedira GmbH

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Celiac Diseases Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Diagnosis Rates Propel Demand for Targeted Therapies
    • Advancements in Biologic Agents Enhance Treatment Efficacy
    • Increased Awareness Spurs Growth in Gluten-Free Product Adoption
    • Expansion of Enzyme Therapies Broadens Treatment Options
    • Regulatory Approvals Accelerate Market Entry of Novel Drugs
    • Growing Prevalence of Celiac Disease Expands Patient Pool
    • Integration of Personalized Medicine Strengthens Treatment Approaches
    • Investment in Research and Development Drives Innovation
    • Technological Innovations in Diagnostic Tools Improve Early Detection
    • Challenges in Adherence to Gluten-Free Diets Highlight Need for Pharmacological Solutions
    • Emergence of Non-Dietary Therapies Opens New Market Segments
    • Globalization of Western Diets Increases Incidence Rates Worldwide
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Celiac Diseases Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Celiac Diseases Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Celiac Diseases Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for First Line Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for First Line Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for First Line Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Second-Line Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Second-Line Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Second-Line Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Parenteral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals & Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals & Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospitals & Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Specialty Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Specialty Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Specialty Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Online Platforms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Online Platforms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Online Platforms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Celiac Diseases Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • JAPAN
    • Celiac Diseases Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • CHINA
    • Celiac Diseases Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: China 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • EUROPE
    • Celiac Diseases Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Celiac Diseases Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Celiac Diseases Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • FRANCE
    • Celiac Diseases Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: France 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • GERMANY
    • Celiac Diseases Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Celiac Diseases Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Spain 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Russia 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Celiac Diseases Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Celiac Diseases Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 16-Year Perspective for Celiac Diseases Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Celiac Diseases Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Australia 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • INDIA
    • Celiac Diseases Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: India 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: South Korea 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Celiac Diseases Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Celiac Diseases Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Latin America 16-Year Perspective for Celiac Diseases Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Argentina 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Brazil 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Mexico 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Celiac Diseases Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Celiac Diseases Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Middle East 16-Year Perspective for Celiac Diseases Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Iran 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Israel 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: UAE 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030
  • AFRICA
    • Celiac Diseases Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Celiac Diseases Drugs by Therapy Type - First Line Treatment and Second-Line Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Africa 16-Year Perspective for Celiac Diseases Drugs by Therapy Type - Percentage Breakdown of Value Sales for First Line Treatment and Second-Line Treatment for the Years 2014, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Celiac Diseases Drugs by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Celiac Diseases Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Celiac Diseases Drugs by Distribution Channel - Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Celiac Diseases Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies and Online Platforms for the Years 2014, 2025 & 2030

IV. COMPETITION